

## Index

### a

acetaminophen 46, 49, 55  
 acid/base relationships 336  
 active pharmaceutical ingredient 4, 25, 33, 144, 179, 262, 321  
 $\alpha$ -lactose monohydrate 31, 33, 46, 56  
 $\alpha$ -motion 97, 337  
 Altman, Richard 10, 14  
 amino acids 94, 102, 141, 201, 271–273  
 annealing 59, 105, 130, 143–146, 248  
 annealing process 130, 143  
 Annear's process 265, 266  
 antiplasticizer 133, 137, 142, 334  
 atomization  
   drying chamber 187–189  
   particle collection 189  
   pressure/hydraulic atomization 185–186  
   rotary atomizers 186–187  
   twin-fluid/gas (air) assisted atomizer 184–185

### b

biologics 1  
 biopharmaceuticals 1, 3, 5, 91, 92, 141, 155, 258, 273–277  
 Borden, Gail 9  
 Bragg's law 98  
 $\beta$ -relaxations 97, 151, 152  
   preservation by foam formation (PFF) 266–268  
   preservation by vaporization (PBV) 268  
 Brunauer–Emmett–Teller (BET) analysis 151, 278

bulking agents 101, 105, 128, 132, 141, 160, 227, 248

### c

capacitance manometers (CM) 147  
 carbon dioxide assisted nebulization (CAN-BD) 133  
 cavitation foam drying (CFD) 268  
 circular dichroism (CD) 96, 124  
 clean-in-place (CIP) 189, 207  
 commercial drying 3, 180  
 computational fluid dynamics (CFD) 157, 158, 183, 185, 190, 367  
 container-closure systems 155–156  
 conventional commercial freeze-dryers 158–159  
 critical micelle concentration (CMC) 325  
 cryoprotectants 99, 140, 248, 249, 286, 291  
 cryoprotection 142, 153  
 current good manufacturing practice (cGMP) 303, 305  
 cyclodextrins (CDs) 67, 102  
 cyclone dryers 35

### d

data visualization 125–126, 134  
 deamidation 91–94, 107, 123  
 deformation stage 197–198  
 degree of supercooling 104, 140, 161, 284, 285, 287, 288, 292, 295  
 $\delta$ -mannitol polymorph 98

- dielectric relaxation 289, 327
  - dielectric relaxation spectroscopy (DRS) 97, 328, 329, 334
  - differential scanning calorimetry (DSC) 29, 92, 97, 124, 151, 152, 277, 308, 328, 365
  - diffuse reflectance (DR) spectroscopy 319, 321
  - dipolar rotation/vibration 239–241
  - directly heated batch dryers 35
  - directly heated (convective) dryers
    - fluidized-bed drying
      - advantages, utility and drawbacks 42
      - characteristics of materials 40
      - granule moisture content and size 41
      - minimum fluidization velocity 39
    - spray drying
      - atomization device 43
      - closed cycle 44
      - drug delivery 52
      - formulation development, role in 44
      - open cycle 44
      - particle engineering 47
      - physical form, impact of 44
      - semi-closed cycle 44
    - tray drying
      - anhydrate→hydrate→incomplete dehydration 38
      - disadvantages 37–39
      - hydrate→anhydrate or dehydrated phase 38–39
      - non-condensable gases 36
      - rate of mass transfer 36
      - removal of moisture 36
      - utility 36–37
  - direct simulation Monte Carlo (DSMC) technique 158
  - disulfide bond formation 92–93
  - Dover, Thomas 12
  - Dover's powder 12
  - dried egg 9
  - droplet formation 102, 106, 107, 227
  - droplet generation technology 225
  - drug delivery systems 52, 54, 67
  - drum dryers 35
  - drying chamber 57, 58, 144, 147, 155, 181–183, 187–189
  - drying materials 33
  - drying phase 107, 198
  - drying processes 3, 305
    - history of
      - dried egg 9
      - fluidized bed drying 16
      - freeze drying 10, 13–15
      - meat biscuit 9
      - mechanical dryer 9
      - pharmaceutical products 11–13
      - spray drying 15–16
      - sun drying 9
      - supercritical drying 16–17
    - implementation 309–310
    - measuring dryness 305–306
    - process considerations 306–307
    - product considerations 307–309
    - scale-up considerations 309
  - drying technology 2–4, 10, 11, 63, 206, 257, 262, 279, 305, 351
  - dry powder inhalers (DPI) 48
- e**
- early stage clinical development strategy 4
  - electric and magnetic field, sublimation process 294–295
  - electron spectroscopy for chemical analysis (ESCA) 151, 273, 278
  - electrostatic charge modulation 125
  - emerging drying technologies
    - microwave drying 68–73
    - super critical fluid (SCF) drying
      - advantages and drawbacks 62–63
      - description 62
      - drug delivery systems 67
      - form control and polymorphism 64–65
      - particle engineering and micronization 65–67
  - equilibration phase 191, 198–200
- f**
- feedstock systems 181

- fine particle fraction (FPF) 49
- Flosdorf, Earl W. 14, 139
- fluidized-bed dryers 30, 32, 35, 39, 40
- fluidized-bed drying 16, 70
  - advantages, utility and drawbacks 42–43
  - characteristics of materials 40
  - granule moisture content and size 41
  - minimum fluidization velocity 39
- fluidized bed system 224
- foam drying
  - advantages of 261–262
  - application
    - buffers and pH 271
    - foaming agents 272
    - glass formers 271–272
    - moisture content 271
    - plasticizers 272
    - polymers 272
    - proteins and amino acids 272–273
  - barriers to change 270
  - case studies 273–277
  - cycle 264
  - drug delivery requirements 270
  - equipment parameters 263–265
  - in food industry 262–263
  - freeze drying 259
  - molecular mobility and amorphous structure analysis 278–279
  - in pharmaceutical industry 263
  - process stresses 269
  - scalability and process robustness 269–270
  - specific surface area and surface composition analysis 278
  - spray drying 259
  - thermal analysis and protein secondary structure 277–278
  - thermal cycle 263–265
  - vacuum foam drying 259–260
  - variants of 266, 268
  - wet blend requirements 265–266
- foaming agents 262, 269, 272
- Fourier transform infrared spectroscopy (FTIR) 92, 96, 124, 273, 278, 365
- freeze-dryers 35, 57, 58, 150, 156
- freeze-drying 3, 10, 13, 33, 259
  - advantages and drawbacks 58
  - air-solution interface 323
  - container-closure systems 155
  - description 57–58
  - drug product development 60–62
  - dryer design
    - commercial scale freeze-dryers 157–160
    - intelligent formulation and process design 160–161
    - laboratory scale dryers 156–157
  - freeze concentration 140
  - ice crystallization 140
  - lyophilization processes 140
  - modelling of 150
  - monitor dried products
    - biologic and formulation matrix 152
    - matrix contributions 151–152
    - process inefficiency 154–155
    - protein degradation 153–154
    - structure of biologic 150–151
  - pharmaceuticals 139
  - phase transformation in formulation components 58–60
  - process 3, 283
    - application AC field to freezing 288–289
    - application to solid materials 287–288
    - application to water and systems with dissolved solute 285–287
    - stages and parameters 284–285
  - process design and monitoring emerging analytical tools 149–150
  - heat flux sensors (HFSs) 148–149
  - mass spectroscopy application 148
  - Pirani gauge for the control of primary drying 147–148
  - pressure decrease method 149

- freeze-drying (*contd.*)
- pressure rise test (PRT)/MTM
    - 146
  - product temperature measurement
    - 145–146
  - SMART Freeze-Dryer™
    - Technology 146–147
    - TDLAS method 149
  - rational formulation design
    - 140–143
  - and spray-drying
    - acid-base relationships 318–322
    - fast beta relaxation 332–336
    - instability 323–325
    - physicochemical stability
      - 325–332
  - freeze foam drying (FFD) 268
- g**
- gear pump systems 186
  - glass formers 271–273, 329, 330, 337
  - glass transition temperature 28, 97,
    - 141, 143, 151, 199–201, 248, 268, 275, 277, 322, 326, 329, 365
  - glycation 92, 94, 107, 123
- h**
- Hammett acidity function 152,
    - 319–322
  - heat flux sensors (HFSs) 148–149
  - high flux backscattering spectrometer (HFBS) 278
  - hot air drying 3, 30
  - humidity drying 37
  - hydrogen bonding 97, 105, 249, 271,
    - 292, 323
- i**
- ice crystallization 140, 143, 144, 153,
    - 265
  - indirectly heated (conductive) dryers
    - 35
    - freeze drying
      - advantages and drawbacks 58
      - description 57–58
      - drug product development 60–62
      - phase transformation in
        - formulation components
          - 58–60
      - rotary drying
        - advantages and drawbacks 57
        - heat-sensitive materials 56
        - wet feed 56
  - injectable/infusible drugs 2, 364
  - ionic conduction 239, 240, 246
- k**
- Karl Fischer (KF)
    - reaction 305
    - titration 41, 99
  - klystrons 242
- l**
- laboratory scale dryers 148, 156–157
  - Leslie, John 13
  - Lewis, Warren K. 10
  - live virus vaccines (LVVs) 122, 357
  - lyophilization 128
    - disruptive lyophilization/drying
      - technologies 369–370
    - equipment for existing and new
      - products 369
    - equipment harmonization and
      - scale-up 368–369
    - freeze-drying 357
    - process 284, 294
      - control and automation 367
      - modeling and simulation 367
      - monitoring instrumentation
        - 366–367
    - products 359, 364
    - regulatory interface 370–371
    - roadmapping process 358–363
    - trends and drivers 363–364
    - workforce development 361, 371
  - lyophilizer 144, 158, 264, 366, 368, 369
- m**
- magnetic field on freezing
    - non-significant effect of 291–294
    - patent claims and studies on
      - 290–291
  - magnetron, generators 242

- manometric temperature measurement (MTM) 146
- microcrystalline cellulose 31, 33
- microwave-assisted freeze-drying 5
- microwave drying 73
  - advantages of 68
  - defined 67
  - pharmaceutical applications 68–73
- microwave freeze drying 241
  - equipment used for 242–246
  - pharmaceutical products 248–249
- microwave heating and drying
  - advantages 251
  - applications, at low temperature 241–242
  - chambers 242–243
  - depth of penetration 247
  - dielectric properties 246–248
  - dipolar rotation/vibration 240–241
  - electric and magnetic fields 240
  - glass transition temperature and collapse 248
  - interpretation of 240
  - ionic conduction 240
  - klystrons and magnetrons generators 242
  - non-uniformity of electromagnetic field 251
  - patents for application 252
  - of pharmaceutical products 248–249
  - safety and microwave leakage control 245–246
  - vaccum systems 243–245
- microwave vacuum drying 69, 132, 134, 260, 263
- modulated differential scanning calorimetry (MDSC) 278
- molecular mobility 28, 39, 59, 151, 152, 271–273, 278–279, 317–337
- monoclonal antibodies 4, 91, 139, 205, 262, 263
- Morland, Samuel 16
- Mudd, Stuart 14
- n**
- Neutron backscattering 142, 152, 334
- N*-glycosylated amines 94
- nifedipine nanoparticles 53
- non-ionic surfactants 102, 143, 274, 325, 337
- o**
- organic solvents 17, 33, 44, 52, 58, 67, 182
- oxidation 91, 92, 94, 106, 107, 123, 318, 331
- p**
- particle collection, spray drying 189
- particle engineering 47–51, 53, 55, 65–67, 189–200, 205
- particle formation
  - deformation stage 197–198
  - equilibration phase 198–200
  - evaporation stage 191–192
  - solidification stage 193–194
- Percy, Samuel R. 10, 15
- pharmaceutical dryers 35
- pharmaceutical formulations 225, 244, 247, 248, 279, 321
- pharmaceutical products 1, 2, 11–13, 17, 248–249, 257, 363
- pH-dependent crystallization 33
- plasticizers 142, 272, 333, 337
- pneumatic dryers 35
- polymers 52, 101–102, 243, 272, 330
- polysorbates 104, 143, 325
- positron annihilation lifetime spectroscopy (PALS) 97, 329, 333
- preservation by vaporization (PBV) 268
- pressure decrease method 149
- pressure/hydraulic atomization 185
- pressure rise test (PRT) 132, 146
- pressure swirl atomizer concept 186
- pressure-swirl design 186
- primary drying stage 28, 57, 249–251, 294, 295, 367
- process analytical technology (PAT) 5, 133, 349, 351, 353
- process analytical testing (PAT) 129
- process inefficiency 154–155, 162

- product temperature measurement
    - 145–146
  - product temperature sensors 145, 160, 367
  - proportional–integral–derivative (PID) controller 159
  - protein adsorption 323, 325, 327
  - protein instabilities 91
  - protein instability, external stresses 91
  - proteins, amino acids 272–273
  - protein stability
    - in dried state
      - amino acids 102
      - glass transition and crystallization 97–98
      - metal ions/HP- $\beta$ -CD/surfactants/buffers 102–103
      - polymers 101–102
      - residual moisture content 98–99
      - sample morphology 98
      - sugar 99–100
      - water replacement hypothesis 96–97
    - in drying 105–106
    - in freezing
      - annealing 105
    - higher order structure 96
    - in lyophilized products 106
    - physical instability
      - deamidation 93–94
      - disulfide bond formation 92–93
      - glycation 94
      - oxidation 94
    - protein formulations, analysis in 95
    - purity tests for proteins 95–96
    - spray-drying
      - droplet formation 106
      - drying phase 107
  - protein-sugar systems 142
- q**
- quality by design (QbD) 129, 219, 304
- r**
- refrigeration systems 156
  - residual gas analyzers (RGAs) 148
  - resistance temperature detectors (RTDs) 145
  - respiratory syncytial virus (RSV) 128, 202
  - robust evaluation process 349
  - Roser and Gribbon 266
  - rotary atomizers 184, 186
  - rotary drying 71
    - advantages and drawbacks 57
    - heat-sensitive materials 56
    - wet feed 56
- s**
- safety assessment toxicology (SA Tox)
    - formulation 127
  - secondary drying stage 57, 250, 294, 295, 367
  - secondary motions 97, 327, 332–334, 337
  - self-emulsifying drug delivery systems (SEDDS) 54
  - shelf freeze drying 220–222, 224, 230
  - Sherwood, Thomas K. 10
  - single dose vs. bulk manufacturing 221–222
  - small-angle neutron scattering (SANS) 324
  - small molecule drug product
    - development
      - active pharmaceutical ingredient 25
      - contraction and densification of granules 30
      - crystalline anhydrate or anhydrous phases 26
      - crystallization 28–29
      - dielectric spectroscopy 28
      - enantiotropic systems 27
      - fluidized-bed dryers 39–43
      - freeze-drying 33
      - granule size and shape 30
      - intra-granular porosity 33
      - in-vivo* drug release and absorption 29
      - moisture/solvent content 25
      - particle size and morphology 28
      - spray drying 33–56

- spray-drying and freeze-drying 28–30
  - surface amorphization 30
  - theophylline monohydrate 26, 27
  - tray dryers or fluidized-bed dryers 36, 39
  - wet granulation 29, 32
  - SMART Freeze-Dryer™ technology 146–147
  - solidification stage 193–197
  - solid-state hydrogen-deuterium exchange mass spectrometry (ssHDX-MS) 150
  - solid-state miscibility 329
  - solid-state photolytic labeling-mass spectrometry (ssPL-MS) 150
  - solubility enhancement 52–55, 220
  - spouted bed dryers 35
  - spray dryers 35, 181, 182, 184, 186, 189, 207
  - spray drying (SD) 15, 33, 71, 132, 259
    - aseptic spray drying 205–209
    - atomization 183–184
    - atomization device 43–44
    - biotherapeutics 202
    - drug delivery
      - solubility enhancement 52–55
      - sustained release 55
      - targeted drug delivery 55–56
    - drying chamber 187–189
    - elements of 180
    - feedstock rheological properties 180–181
    - formulation development, role in 44–56
    - open cycle 44
    - particle collection 189
    - particle engineering 47–51
    - particle formation
      - deformation stage 197–198
      - equilibration phase 198–200
      - evaporation stage 191–192
      - solidification stage 193–194
    - physical form, impact of 44–47
    - semi-closed cycle 44
    - vaccine formulations 203
  - spray freeze drying (SFD) 133, 369
  - droplet generation technology 225–226
  - fluid bed processes 224
  - freezing technology 226
  - industrial application 231–233
  - process consideration 227, 230
  - process considerations 222–224
  - product innovation potential 233–235
  - rotary freeze dryer 229–230
  - single dose vs bulk manufacturing 221–222
    - supply chain flexibility 235
  - static foam formation 264
  - sterilization systems 207
  - sublimation 13, 14, 33, 130, 140, 146–149, 158, 159, 221, 249
  - sublimation energy 221, 225, 230, 244
  - sub-optimal condenser design 158
  - sugar 99–100
  - sun drying 9, 13
  - super critical fluid (SCF) drying 72
    - advantages and drawbacks 62–63
    - description 62
    - drug delivery systems 67
    - form control and polymorphism 64–65
    - particle engineering and micronization 65–67
  - surface amorphization 33
- t**
- targeted drug delivery 31, 52, 55, 61
  - temperature sensors 145, 146, 156, 159, 160, 367
  - terahertz time domain spectroscopy (THz-TDS) 333
  - thermal activity monitor (TAM) 278
  - thermally stimulated depolarization current (TSDC) technique 278, 329
  - thermal stress 124, 186, 369
  - thermocouples 132, 145
  - thermogravimetric analysis (TGA) 97, 99, 306

- three dimensional computational fluid dynamic (CFD) modeling tools 182
  - tray dryers 30, 35, 36
  - tray drying
    - anhydrate→hydrate→incomplete dehydration 38
    - disadvantages 37–39
    - hydrate→anhydrate or dehydrated phase 38–39
    - non-condensable gases 36
    - rate of mass transfer 36
    - removal of moisture 36
    - utility 36–37
  - trehalose 27–29, 100–102, 105, 141, 142, 193
  - Truong 268
  - tunable diode laser absorption spectroscopy (TDLAS) 149
  - turbo-tray dryers 35, 36
- V**
- vaccine drug product development
    - developability 122–124
    - formulation development 127–129
    - late-stage development 129–132
    - pre-formulation development
      - biophysical characterization 124–125
      - data visualization 125–126
      - liquid vs. freeze-dried dosage forms 126–127
    - vacuum systems 243
    - vacuum dryers 35
    - vacuum foam drying 257–261, 263, 264, 266, 269
    - vibrated bed dryers 35
- W**
- water crystallization 291, 318
  - water replacement hypothesis 96–97
  - wet blend requirements 265–266
  - wireless sensors 146
  - Wollaston, William H. 13
  - Worthington, Henry R. 16
  - Wurster fluidized bed drying 32, 42
- X**
- X-ray powder diffraction (XRPD) 27, 97, 278, 330